Haematology 2018

Anti-CTLA-4 (CD152) Ipilimumab first approved immunoregulatory mAb

N Engl J Med. 2010 Aug 19;363(8):711-23.

Median OS 10.0 months - ipilimumab plus gp100, vs 6.4 months gp100 alone (HR for death, 0.68; P<0.001). Median OS with ipilimumab alone was 10.1 months .